Condition Guide

Peptides for Female Sexual Dysfunction

PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women. It works through central nervous system pathways, unlike vasoactive ED drugs.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

How peptides help

Bremelanotide activates MC4R in the hypothalamus, driving sexual arousal centrally. It is used on-demand (subcutaneous injection) and is effective in women who do not respond to or tolerate other treatments.

Peptides researched for female sexual dysfunction

PT-141

Strong EvidenceL5

FDA approved (Vyleesi) for HSDD in premenopausal women.

56 studies · Melanocortin MC4R Agonism

State of the evidence

Phase III RECONNECT trials supported FDA approval in 2019. Side effects include nausea and transient blood pressure elevation.

Frequently asked

Is PT-141 FDA approved?

Yes — bremelanotide (brand name Vyleesi) is FDA approved for premenopausal HSDD as of 2019.

Related conditions

Erectile Dysfunction

Melanocortin peptides work centrally — distinct from PDE5 inhibitors like sildenafil.